Heterologous antilymphocyte globulin.

Abstract

THE immunosuppressive properties of heterologous antilymphocyte serum and its globulin derivative have been well known since 1961, when it was reported that a variety of immunologic responses could be weakened in guinea pigs by the administration of the antilymphocyte serum or its globulin derivative that had been raised in rabbits.¹ These included the marked suppression of delayed cutaneous hypersensitivity, a lesser effect on humoral-antibody formation and a relatively feeble mitigation of skin homograft rejection. Soon afterward, it was unequivocally demonstrated^{2 3 4 5} that rabbit antilymphocyte serum had remarkable ability to prolong the viability of mouse or rat skin grafts even when they . . .